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a  b  s  t  r  a  c  t
The  mechanism  of  action  of  the  combination  therapy,  naltrexone/bupropion  (NB),  for  obesity  has  not
been  fully  described  to date. Weight  loss attempts  rarely  result  in  long-term  success.  This  is likely  a
result  of complex  interactions  among  multiple  peripheral  and  CNS  systems  that  defend  against  weight
loss,  and  may  explain  the  overwhelming  lack of  effective  obesity  treatments.  NB is  an  investigational
combination  therapy  for obesity  that  was  developed  based  on  evidence  that  obesity  involves  alterations
in  the  hypothalamic  melanocortin  system  as  well  as  brain  reward  systems  that  inﬂuence  food  craving
and  mood.  Naltrexone  and  bupropion  both  have  actions  in  these  brain  regions  that  may  cause  them  tobesity
eight loss
ood intake
rug interactions
ood craving
eward system
inﬂuence  food  intake,  food  craving,  and  other  aspects  of  eating  behavior  that  affect  body  weight.  We
review  the  individual  actions  of naltrexone  and  bupropion  in  brain  hypothalamic  and  reward  systems,
and  describe  the  current  in  vitro,  in  vivo, and clinical  evidence  for  how  NB  inﬂuences  food  intake  and
produces  weight  loss.
©  2014  The  Authors.  Published  by  Elsevier  Ltd. This  is an  open  access  article  under  the CC  BY-NC-ND
license  (http://creativecommons.org/licenses/by-nc-nd/3.0/).ypothalamus
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. Overview of obesity and current obesity
harmacotherapies
Obesity increases the risk for diabetes, cardiovascular disease,
steoarthritis, cancer, and early mortality [1]. Since the mid  1970s,
he incidence of adult obesity has doubled, while the incidence of
verweight/obesity in children, adolescents and young adults has
ripled [2,3]. Currently, 36% of adults and 17% of children in the
nited States are considered obese [4,5]. This has occurred in spite
f public health advice about the beneﬁts of exercise and reducing
aloric intake. The increasing prevalence of obesity and its comor-
idities has been predicted to account for 16–18% of US health care
osts by 2030 [6] and to initiate the ﬁrst decrease in life expectancy
n modern history [7]. Behavioral interventions such as diet and
xercise are the most common treatments for weight loss, but many
verweight and obese individuals are unable to achieve moderate
eight loss with behavioral intervention alone [8]. The increase in
he prevalence of obesity is a clear indication of the failure of behav-
oral intervention to produce sustained and meaningful weight loss
n today’s obesogenic environment, and highlights the need for
dditional methods of weight loss.
Obesity is generally regarded as a chronic disease requiring con-
inuous intervention to maintain ideal body weight [8,9]. Of the
ew treatments available for obesity, bariatric surgery is the most
ffective, resulting in weight loss of about 25% at 2 years post-
urgery and improvements in many cardiometabolic risk factors
10,11]. Common limitations of bariatric surgery include peri- and
ost-operative complications, cost, and access. Bariatric surgery is
ssociated with a 7.3% peri-operative complication rate, a 1.6–3.5%
ncidence of serious complications, conversions and reoperations,
eight regain, and recurrent binge-eating [10,12].
Pharmacological treatments for obesity offer a less invasive
lternative to bariatric surgery but the ﬁeld has been hampered
y few treatment options, limited efﬁcacy, and uncertainty about
he safety of long-term use in the general population. In recent
ears, the high-proﬁle withdrawal of obesity drugs (e.g., sibu-
ramine) from the market due to safety issues has left physicians
ith few treatment options, increased concern about the safety
f pharmacotherapy options, and caused confusion about how
o effectively manage obesity. Recent approval of 2 new obesity
rugs by the FDA in 2012 increased the total to 3 FDA-approved
ong-term pharmacological treatments for obesity: orlistat, lor-
aserin, and the combination of phentermine and topiramate [13].
rlistat is a lipase inhibitor that reduces the body’s ability to
bsorb fat from food. Weight loss with orlistat is modest, ran-
ing from 2% to 4% greater than placebo [14–17]. Lorcaserin is a
erotonin receptor (5-HT2C) agonist that causes selective activa-
ion of CNS serotonin receptors. It was designed to avoid the side
ffect of serotonin-associated valvulopathy previously seen with
on-selective serotonin-receptor agonists such as fenﬂuramine. At
 year, placebo-subtracted weight loss with lorcaserin is about
% in the intent-to-treat population or 4% in study completers
study participants who remained on drug for the duration of the
tudy) [18–20]. Phentermine has been approved for short-term
besity treatment since 1959, and topiramate is an anticonvulsant
hat has shown weight-loss effects [21]. Various doses of phenter-
ine/topiramate produced placebo-subtracted weight loss of 4–9% .  .  . . . . .  .  . .  .  . . . . .  . . . . .  . . .  .  . . . .  . . . .  . . .  . . . .  . . .  . . . .  . . . . . . .  .  . . . .  .  . . . .  .  .  .  .  . .  .  . .  .  .  8
after 1 year of treatment in the intent-to-treat population or 5–12%
in study completers [22–24].
With the exception of orlistat, which has a clear peripheral
mechanism of action, lorcaserin and phentermine/topiramate are
presumed to produce weight loss via actions in the brain, though
the exact mechanisms are unknown [25]. They are presumed to
reduce food intake by inﬂuencing appetite or eating behavior,
though they may also have other effects that contribute to weight
loss. Many physiological processes that reduce appetite also recip-
rocally regulate energy expenditure, although this has not been
formally assessed in humans with any of the therapies discussed
here.
2. Obesity and the brain
Body weight is inﬂuenced by energy intake and expenditure,
both of which are regulated by the brain [26]. Brain systems that
balance energy intake and expenditure are biased toward weight
conservation in most individuals. This appears to make evolu-
tionary sense, as weight conservation would protect against food
shortage. Weight loss is often associated with reduced energy
expenditure [27], requiring a greater reduction in caloric intake
in order to maintain reduced body fat. Additionally, the intrinsic
reward value of food often promotes consumption of more calories
than necessary, resulting in weight gain over time [26].
Obesity is associated with alterations in neural signaling. Differ-
ences in neural responses to hunger and satiation are documented
in obese vs. lean individuals [28] and women appear to exhibit
lower cognitive control of brain responses to food stimuli than men
[29]. Persistence of abnormal neural responses to a meal in for-
merly obese individuals, a group at high risk for relapse, indicates
that a tendency to obesity may  involve areas of the brain that con-
trol complex aspects of eating behavior including anticipation and
reward, chemosensory perception, autonomic control of digestion,
and memory [30]. Weight loss is also associated with increases in
neural activity in brain regions involved in reward processing and
valuation of food stimuli, as well as decreased activity in regions
involved in restraint in response to food [31,32]. These changes
likely drive the delayed satiation, decreased perception of caloric
intake, and increased hunger observed after a 10% weight loss [33].
Furthermore, dieting is associated with increases in food preoc-
cupation and food craving [34,35]. Consequently, signiﬁcant and
sustained weight loss in overweight or obese individuals is often
accomplished by signiﬁcant increases in dietary restraint or eating
control [36,37]. Considering the broad availability of aggressively
marketed, highly palatable food in developed countries, obesity
drugs that reduce hedonic feeding behavior may be especially help-
ful [38,39]. Some of the currently available obesity therapies are
thought to produce weight loss by inﬂuencing reward-mediated
eating behavior through a variety of CNS mechanisms, though fur-
ther study is needed [39].
2.1. Brain regions that inﬂuence energy balance2.1.1. The hypothalamic melanocortin system
The melanocortin system in the hypothalamus (Fig. 1) is a fun-
damental component of CNS regulation of homeostatic energy
S.K. Billes et al. / Pharmacologica
Fig. 1. Homeostatic (hypothalamus) and hedonic (reward system) regulation of
energy balance. The hypothalamus (green) is important for regulation of homeo-
static energy balance, while the reward system (blue) is important for processing
the rewarding aspects of food and food-related stimuli. The reward system includes
dopamine pathways that originate in the ventral tegmental area (VTA) or substantia
nigra and project to regions including the striatum (movement, reward salience),
nucleus accumbens (reward, addiction), prefrontal cortex (decision making, exec-
utive function), and amygdala (memory, emotion). The hypothalamus consists of
cells that detect and integrate information related to energy state, such as glucose,
leptin, and insulin. The lateral hypothalamus projects to the VTA, and also receives
input from regions such as the nucleus accumbens. These connections are important
for integrating the rewarding and homeostatic aspects of food seeking, avoidance,
and other aspects of eating behavior. (For interpretation of the references to color
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administration of naltrexone increases POMC  mRNA [95]; this
would be expected to restore activity of POMC neurons andn  this legend, the reader is referred to the web version of the article.)
alance [40]. Cells in this brain region detect and integrate blood-
orne and neural signals that relay information concerning energy
vailability to inﬂuence food intake and energy expenditure. Two
ey cell populations in the melanocortin system reside in the arcu-
te nucleus of the hypothalamus: pro-opiomelanocortin (POMC)
ells and agouti-related peptide (AgRP) cells. These cells produce
eptides that competitively bind to the melanocortin-4 receptor
MC4R) [41–44]. POMC cells produce -melanocyte stimulating
ormone (-MSH), an MC4R agonist. Stimulation of the MC4R
y -MSH produces an overall anorexic effect, increasing energy
xpenditure and decreasing appetite in both animals and humans
45,46]. Conversely, AgRP is an MC4R antagonist that competitively
locks -MSH, resulting in increased food intake and energy con-
ervation [47].
Signals that stimulate POMC cells (such as leptin, an adipose
issue-derived hormone that can reduce food intake and body
eight) generally produce an anorexic effect [48,49], whereas sig-
als that stimulate AgRP cells (such as ghrelin, a hunger-stimulating
ormone produced in the stomach), reduce energy expenditure
nd increase appetite [40,50–52]. Therefore, agents that stimulate
OMC activity have been developed as possible obesity thera-
ies, though few agents have been successful. One reason for the
ack of success thus far may  be that the melanocortin system is
quipped with feedback mechanisms that limit sustained stimula-
ion of POMC cells.
The endogenous opioid, -endorphin, is produced from the
OMC precursor peptide and is released from POMC cells along
ith -MSH [53,54]. POMC cells are inhibited by opioids such
s -endorphin via stimulation of the -opioid receptor [55].
hus, -endorphin is thought to act as an autoinhibitor of POMC
eurons [48,56]. Mice that develop obesity and insulin resis-
ance through chronic maintenance on a high-fat diet [57] have
ncreased hypothalamic -endorphin [58]. It is possible that
his increase in -endorphin, coupled with decreased sensitiv-
ty to anorexic signals [59], contributes to the development of
besity. In normal weight animals, blockade of the -opioid
eceptor results in increased POMC activity [48]. Thus, blocking
-endorphin-mediated autoinhibition of POMC neurons with al Research 84 (2014) 1–11 3
-opioid antagonist may  block this counter-regulatory pathway
and facilitate weight loss in obesity.
2.1.2. The reward system
The mesocorticolimbic dopamine system (reward system) origi-
nates in the midbrain and projects to forebrain areas including the
ventral striatum, prefrontal cortex and amygdala (Fig. 1) [60,61].
The reward system plays a central role in regulation of eating
behavior by mediating the rewarding effects of pleasurable stimuli
(food, sex and drugs of abuse) and governs reward-directed behav-
ior [26,39,60,62,63].
In the reward system, dopamine and opioid systems facilitate
feeding in an interdependent manner [64]. Dopamine release in
the ventral striatum mediates the association between food and the
positive experience of eating that food, which drives the degree of
‘wanting’ or desire for certain foods [65]. Dopamine also regulates
the activity required for food seeking behavior [66]. In contrast,
striatal opioids modulate the ‘liking’, or pleasurable feeling of
rewarding stimuli [67,68]. In other words, whereas opioids con-
vey the reward sensation of palatable foods, dopamine regulates
the reward value of food and how hard we  are willing to work to
obtain that reward.
The availability of highly palatable food increases reward-based
or hedonic feeding in humans and animals [69] and individual dif-
ferences in the neurophysiology of the reward system have been
identiﬁed that may  explain why certain individuals are at greater
risk for weight gain [70,71]. Furthermore, the reward system can
undergo neuro-adaptations in response to chronic exposure to
rewarding stimuli and it appears that similar changes occur in
obesity [72,73]. In animals and humans, obesity is associated with
alterations in striatal dopamine signaling [70,74–78]. Physiological
signals like leptin were originally thought to act primarily in the
hypothalamus; however, they also inﬂuence activity of dopamine
cells in the reward system [79–83]. In obesity, the sensitivity of the
reward system to signals such as leptin may  be impaired [84,85].
3. Individual effects of naltrexone and bupropion on
energy balance
The naltrexone/bupropion combination (NB) is an investi-
gational obesity therapy that was developed to target neural
pathways that regulate homeostatic food intake and energy expen-
diture [86,87] as well as hedonic eating behavior and decision
making [35]. Preclinical and clinical studies with naltrexone and
bupropion indicate that these agents may  act in homeostatic and
reward pathways to inﬂuence food intake and body weight [88].
3.1. Naltrexone
Naltrexone is an opioid antagonist with a high afﬁnity for
the -opioid receptor. Approved for treatment of alcoholism and
opioid addiction [89–91], naltrexone inﬂuences eating behavior
in animals. The hypothalamic melanocortin and reward sys-
tems contain opioid neurons [92,93], hence naltrexone activity
may  inﬂuence food intake and body weight via these dual sys-
tems.
Although there are several opioid receptors, genetic and phar-
macological preclinical studies implicate the -opioid receptor in
eating behavior. Mice engineered to lack the -opioid receptor
are resistant to obesity induced by a high fat diet [94]. Chronicmelanocortin satiety systems [96,97]. These results are consistent
with the hypothesis that naltrexone blocks -endorphin action
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t the -opioid receptor, thus preventing autoinhibition of POMC
eurons.
Studies in animals indicate that acute naltrexone administra-
ion inﬂuences activity of the reward system and hedonic eating
ehavior. Systemic naltrexone prevents the increase in dopamine
n the nucleus accumbens caused by food ingestion and also reduces
ood intake [98], food seeking, and binge-like eating [99,100]. Direct
njection of naltrexone into the reward system (nucleus accum-
ens and ventral tegmental area) can reduce preference for highly
alatable foods, especially foods that are high in fat and sugar
101–104], as well as expression of ﬂavor preference [105,106],
reference for palatable diets following periods of abstention [107],
nd binge-like eating [100]. Naltrexone produces a more profound
eduction in food intake in animals in which endogenous opioid
ystems have been modiﬁed by chronic intake of a high fat diet
108,109].
Human studies also demonstrate that opioids can inﬂuence
ngestive behavior by modulating subjective palatability. Con-
istent with the role of opioids in the rewarding aspects of
ating, naltrexone reduces the subjective pleasantness, or liking,
f certain foods (especially palatable foods); this effect is inde-
endent of nausea, a common side effect of naltrexone [110,111].
owever, early reports that naltrexone monotherapy reduces
ood intake [112] and body weight [113] were largely unsub-
tantiated by subsequent placebo-controlled double-blind studies
cross a range of doses (50–300 mg/day) [114–117]. Although one
tudy found that weight loss was signiﬁcant in obese women
hen results were analyzed by sex [118], this ﬁnding has not
een replicated. Thus, despite promising preclinical data, naltrex-
ne monotherapy-mediated blockade of opioid neurotransmission
s insufﬁcient to produce reliable decreases in food intake in
umans.
.2. Bupropion
Bupropion is an atypical antidepressant currently approved as
n aid in smoking cessation and for the treatment of depression
nd seasonal affective disorder [119–121]. Bupropion inhibits reup-
ake of the catecholamines dopamine and norepinephrine, and is
 weak nicotinic acetylcholine receptor antagonist [122]. By block-
ng the removal of synaptic dopamine and norepinephrine, acute
eripheral treatment with bupropion produces transient changes
n extracellular dopamine and norepinephrine concentrations in
he brain [123,124] and may  also alter the activity of the neurons
hat release dopamine and norepinephrine [119,125].
Activity of the melanocortin system is inﬂuenced by both
opamine and norepinephrine [126,127], and reduced dopaminer-
ic tone in the hypothalamus is associated with various elements
f obesity [128]. Thus, the hypothalamic melanocortin system is
 potential site of bupropion action. Indeed, bupropion stimulates
ctivity of POMC cells in vitro [117] and increases -MSH secretion
Billes & Cowley, unpublished observations). In addition, bupro-
ion’s antidepressant effects and efﬁcacy as a smoking cessation
id are consistent with actions in the reward system [129].
Bupropion reduces short-term food intake in lean and obese
odent models and increases energy expenditure by increasing heat
roduction [130–136], although the overall effect of bupropion
n body weight in animals is modest [133]. In humans, weight
oss is a common side effect of bupropion use for the treatment
f depression [121]. In overweight and obese adults, bupropion
300–400 mg/day) for up to 6 months resulted in modest placebo-
ubtracted weight loss of 2–4% (by intent-to-treat analysis) and
–5% in study completers [116,117,137–139]. The effect of bupro-
ion on caloric intake in humans has never been studied directly.
arly reports indicating no effect of bupropion on food intake werel Research 84 (2014) 1–11
not designed to address this issue and further study is warranted
[140,141].
4. Preclinical studies with the naltrexone/bupropion
combination
4.1. Naltrexone/bupropion action in the melanocortin system
The combination of naltrexone and bupropion was originally
developed based on in vitro studies in the mouse hypothala-
mus. Cowley and colleagues demonstrated that bupropion acutely
increases activity of POMC cells that express enhanced green ﬂu-
orescent protein (POMC-EGFP) [117]. It was  hypothesized that the
-opioid receptor, which mediates autoinhibition of POMC cells
by -endorphin [48,56], limits the effect of bupropion on increas-
ing POMC activity, resulting in the modest effects of bupropion
monotherapy on weight loss and caloric intake described in Section
3.2. Blockade of the -opioid receptor with naltrexone alone grad-
ually increases POMC activity; however, simultaneous application
of bupropion and naltrexone produces a larger increase in POMC
activity (Fig. 2) [117]. Thus, the naltrexone/bupropion combination
is thought to do the following: stimulate POMC cells (bupropion)
while also removing the natural -endorphin “brake” on POMC
cells (naltrexone) (Fig. 3). These electrophysiological studies were
the basis for further investigation of the naltrexone/bupropion
combination in vivo.
4.2. Naltrexone/bupropion action in the reward system
Injection of bupropion alone or naltrexone alone directly into
the reward system is sufﬁcient to reduce food intake in hungry
mice [142]. However direct injection of naltrexone and bupro-
pion produces a synergistic (greater than additive) reduction in
food intake (Fig. 4) [142], indicating that naltrexone and bupropion
each have independent and complementary actions in the reward
system.
4.3. Systemic effects of naltrexone/bupropion
As discussed, systemic administration of either naltrexone or
bupropion produces a dose-dependent reduction in food intake
in fasted normal weight (lean) mice [117,134] and rats [136].
Coadministration of naltrexone and bupropion produces a greater
reduction in food intake that is comparable to the added effects
of each drug [117,136]. In mice that are obese after long-term
maintenance on a high-fat diet (diet-induced obese [DIO] mice),
systemic naltrexone and bupropion each reduce food intake inde-
pendently, and the combination produces a synergistic decrease in
food intake [117]. In DIO rats, combined administration of naltrex-
one and bupropion also reduces food intake and body weight and
results in loss of fat mass [136].
4.4. Summary of preclinical studies
Preclinical studies demonstrate that naltrexone and bupropion
have independent actions in 2 brain regions that inﬂuence energy
balance. In the melanocortin system, bupropion stimulates activity
of POMC cells and this action is ampliﬁed by the addition of naltrex-
one, which blocks the endogenous opioid-mediated brake (Fig. 3).
These effects are consistent with reduced food intake, increased
energy expenditure, and weight loss over time. Additionally, nal-
trexone and bupropion act directly in the reward system to produce
a synergistic effect on food intake; these actions likely inﬂuence the
relative reward value of food and the activity required for food con-
sumption. Finally, the acute effects of the naltrexone/bupropion
combination on food intake are maintained in an obese rodent
model.
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Fig. 2. Effect of naltrexone and bupropion on activity of POMC cells. Appli-
cation of bupropion (10 mol/L), naltrexone (1 mol/L) and naltrexone
(1  mol/L) + bupropion (10 mol/L) to mouse hypothalamic slices containing
arcuate POMC-EGFP cells. Combined application of naltrexone and bupropion was
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Fig. 3. Mechanism for naltrexone/bupropion action in the hypothalamic
melanocortin system. The hypothalamus contains cells that produce pro-
opiomelanocortin (POMC). In these cells, POMC is cleaved into peptides including
-melanocyte stimulating hormone (-MSH) and -endorphin, which are co-
released from POMC cells. -MSH stimulates the melanocortin-4 receptor (MC4R),
which leads to decreased food intake, increased energy expenditure and weight
loss.  -Endorphin binds to the inhibitory -opioid receptor (MOP-R) on POMC  cells
and acts like a brake to reduce activity of POMC cells. Bupropion stimulates activity
of  POMC cells, increasing POMC production and release of -MSH and -endorphin.
Naltrexone blocks the MOP-R and prevents the -endorphin-mediated feedback
bupropion SR (NB32) occurred as early as Week 4 and was sustained
for at least 56 weeks [144–147]. In the Contrave Obesity Research
(COR) clinical studies (Table 1), overweight and obese subjects were
treated with NB32 or placebo for 56 weeks.
Fig. 4. Synergistic effect of intra-VTA naltrexone/bupropion on food intake in ani-
mals. Effect of intra-VTA injection of vehicle control, bupropion (1 g), naltrexonessociated with a transient increase POMC cell activity. Shading indicates duration
f drug application.
igure adapted from Greenway et al. [117]. Author retains copyright.
. Clinical studies with the naltrexone/bupropion
ombination
Initial Phase 2 clinical studies compared the naltrex-
ne/bupropion combination (NB) with naltrexone or bupropion
onotherapy or placebo for weight loss in obese subjects for up
o 24 and 48 weeks [116,117]. These studies demonstrated that
he NB combination produced greater weight loss than would be
xpected based on the individual monotherapies. In the larger
ose-ranging study that led to Phase 3 dose selection, NB-treated
ubjects had more than twice as much weight loss as those in
he bupropion monotherapy group [116]. In addition, NB was
ssociated with corresponding reductions in abdominal (visceral)
nd total body fat [143]. The results of these early clinical studies
re consistent with preclinical ﬁndings showing a greater than
dditive acute effect of the two monotherapies on activity of POMC
ells and inhibition of food intake.autoinhibition of POMC cells. Together, the naltrexone/bupropion combination
produces a greater increase in POMC activity than either drug alone. This increased
POMC activity is thought to contribute to weight loss in humans.
Subsequent Phase 3 studies extended Phase 2 ﬁndings by
demonstrating that weight loss with a ﬁxed combination of
32 mg/day naltrexone sustained-release (SR) plus 360 mg/day(1  g), or naltrexone (1 g)/bupropion (1 g) on 1-h food intake in mice fasted
overnight. Data are mean (SD). *p < 0.01 compared to vehicle. #p = 0.0025 for an
interaction between bupropion and naltrexone.
Figure adapted from Sinnayah et al. [142].
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Table 1
Weight loss with NB32 in Phase 3 trials in subjects who completed 56 weeks of treatment.
Trial Study description Randomized
subjects, N
Proportion of subjects
in  completer
populationa (%)
Weight lossa (%) Subjects with ≥5%
weight lossa (%)
Subjects with ≥10%
weight lossa (%)
NB32 Placebo NB32 Placebo NB32 Placebo
COR-I 56 weeks of NB32 or placebo in
overweight and obese adultsb
1742 50% 8.1 ± 0.5* 1.8 ± 0.5 62%* 23% 34%* 11%
COR-II 56 weeks of NB32 or placebo in
overweight and obese adultsb
1496 54% 8.2 ± 0.4* 1.4 ± 0.5 65%* 22% 39%* 8%
COR-BMOD 56 weeks of NB32 or placebo
plus intensive lifestyle
modiﬁcation in overweight
and obese adultsb
793 51% 11.5 ± 0.6* 7.3 ± 0.9 80%* 60% 55%* 30%
COR-DM 56 weeks of NB32 or placebo in
overweight and obese adults
with type 2 diabetes
505 54% 5.9 ± 0.5* 2.2 ± 0.6 53%* 24% 26%* 8%
NB32: 32 mg/day naltrexone sustained-release (SR) plus 360 mg/day bupropion SR. The COR-I study also included another treatment group with a lower dose of naltrexone,
NB16  (16 mg/day naltrexone SR plus 360 mg/day bupropion SR; data not shown). In the COR-II study, subjects were maintained on NB32 until weeks 28–44, when subjects
who  did not maintain at least 5% weight loss were re-randomized to either NB32 or a higher dose of naltrexone, NB48 (48 mg/day naltrexone SR plus 360 mg/day bupropion
SR).  NB32 includes all NB32 treatment groups in the 4 COR studies (data for participants in the COR-II study re-randomized to NB32 were double-weighted and participants
re-randomized to NB48 were excluded). In the COR-BMOD study, subjects in both the NB32 and placebo treatment groups received intensive lifestyle modiﬁcation.
a For subjects who completed 56 weeks of treatment and who  were included in the completers analysis.
b Includes BMI  between 30 and 45 or BMI  between 27 and 45 and controlled hypertension and/or dyslipidemia.
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.1. Efﬁcacy
The COR-I study tested the effect of NB32 and a lower dose
f naltrexone/bupropion, NB16 (16 mg/day naltrexone SR plus
60 mg  bupropion SR) compared to placebo [144]. The COR-II
tudy was similar to the COR-I study, except that NB32-treated
ubjects who did not maintain at least 5% weight loss were re-
andomized to either NB32 or a higher dose of naltrexone, NB48
48 mg/day naltrexone SR plus 360 mg/day bupropion SR), to test
f increasing the dose of naltrexone would result in additional
eight loss [146]. Subjects who were re-randomized to NB48
xhibited similar weight loss as those who continued to take
B32, thus, NB48 was not investigated further. Weight loss in
ubjects treated with NB32 for 56 weeks (study completers) was
imilar in COR-I and COR-II, ranging from 8.1% to 8.2% compared
o placebo weight loss of 1.4–1.8% in study completers (Table 1
nd Fig. 5). Weight loss in the intent-to-treat population using
ig. 5. Weight loss with NB32 in COR-I and COR-II. Mean (SEM) body weight by
isit among subjects who completed 56 weeks of treatment in the COR-I and COR-
I  studies. Data for participants in the COR-II study re-randomized to NB32 were
ouble-weighted and participants re-randomized to NB48 were excluded.the last-observation-carried-forward (LOCF) method was 6.1% and
6.4% with NB32 compared to 1.2% and 1.3% with placebo. In both
studies, a greater proportion of NB-treated subjects lost at least
5% or 10% of their baseline bodyweight. Compared to placebo,
NB32-treatment was associated with larger improvements in
cardiometatoblic risk factors such as waist circumferences, lipids,
and insulin resistance, as well as weight-related quality of life.
The COR-BMOD study tested the effects of combining NB32 or
placebo with an intensive behavior modiﬁcation program designed
for weight loss (Table 1) [145]. NB32 resulted in weight loss in
addition to that produced by the intensive behavior modiﬁcation
program alone (placebo), as well as improvements in obesity-
related risk factors. The fourth COR study, COR-DM, was conducted
to test the effect of NB32 in patients with type 2 diabetes mellitus
who were not taking any diabetes medication or who  were taking
a stable dose of oral diabetes medications (e.g., metformin, sul-
fonylureas, or thiazolidinediones, or DPP-4 inhibitors) [147]. NB32
resulted in greater weight loss than placebo, regardless of concur-
rent diabetes medication.
The effect of NB32 on smoking cessation and major depressive
disorder in overweight and obese adults has also been investigated
in two small open-label studies. In overweight and obese smok-
ers, 24 weeks of open-label NB32 was  associated with decreased
nicotine use and the absence of weight gain, a common side effect
of smoking cessation [148]. Another study evaluating open-label
NB32 for 24 weeks in overweight and obese women with major
depressive disorder demonstrated that NB32 was associated with
weight loss and improvements in multiple measures of depressive
symptoms [149]. These ﬁndings are consistent with the efﬁcacy of
bupropion in treating depression and as an aid in smoking cessa-
tion. They illustrate the potential for NB to produce weight loss or
prevent weight gain in speciﬁc populations that warrants further
study.
5.2. Control of eatingPreclinical data and an understanding of the CNS pathways that
are likely inﬂuenced by NB32 treatment suggest that improvement
in reward-based eating and craving-related behavior may  be at
least partially responsible for the weight loss observed with NB32.
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Fig. 6. Effect of NB32 on control of eating. Mean (SEM) change in CoEQ question 19,
“Generally, how difﬁcult has it been to control your eating?” from baseline to Week
8  through 56 for the intent-to-treat population using the last-observation-carried-
forward method. NB32 includes all NB32 treatment groups in the 4 COR studies,
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parable to the three obesity pharmacotherapies currently available
for long-term use in the United States: orlistat, lorcaserin, andnd subjects who were switched from NB32 to NB48 in the COR-II study. *p < 0.05
s.  placebo.
ndeed, subject-reported outcome data from the COR studies indi-
ates that NB32 may  inﬂuence appetite and food cravings.
The Control of Eating Questionnaire (CoEQ) was  administered
n all COR studies. The CoEQ consists of a series of 20 visual ana-
og scales [150] designed to assess various aspects of appetite, food
raving, eating behavior and mood [151]. In particular, the control
f eating measure (CoEQ 19: Generally, how difﬁcult has it been to
ontrol your eating?) was a pre-speciﬁed secondary endpoint in 3
f the 4 COR studies. In all 4 COR studies, NB32-treated subjects
eported improved ability to control their eating (CoEQ 19) com-
ared to placebo [88,144–146,152]. In an integrated analysis of all 4
OR studies, NB32 was associated with signiﬁcant improvement in
oEQ 19 compared to placebo at all time points measured, including
he earliest measure at Week 8 (Fig. 6). Additionally, improvement
n CoEQ19 at Week 8 was positively correlated with weight loss
t the end of the studies [152]. NB32 was also associated with
mprovements in other measures, including the increased ability
o resist food cravings as well as reduced incidence and strength of
ood cravings.
Though preliminary results from the CoEQ suggest overall
mprovement in the general frequency, intensity, and ability to
esist food cravings, no treatment differences were observed with
espect to craving of speciﬁc types of food, which were assessed
y the Food Craving Inventory [153]. These results are a reminder
f the complexity of measuring food intake in humans; many psy-
hological and physiological factors inﬂuence responses in a given
opulation during a weight loss study [35,39].
An fMRI study compared the effects of 4 weeks of treat-
ent with NB32 or placebo on brain activity in response to
ood images in fasted overweight and obese women  [154]. Com-
ared to placebo, NB32 was associated with reduced hypothalamic
ctivation and increased activation of forebrain regions (dorsal
nterior cingulate, superior frontal, posterior insula, hippocampal,
nd superior parietal regions) involved in self control, awareness,
emory, and sensory processing. The forebrain regions identi-
ed in this study interact with the reward system to regulate
ating behavior and are implicated in obesity [155]. Brain imag-
ng studies in humans show that hypothalamic activation in
esponse to food cues is increased during the fasted state, and
hat this activation is attenuated after overfeeding in lean [156],
ut not overweight, obese [157], or weight-reduced individuals
158]. Although the mechanism for these changes in brain activity
equires further study, these results suggest that NB32 may  restore
he impaired hypothalamic response to satiety in obese individ-
als and improve forebrain control of behavior in response to food
ues.l Research 84 (2014) 1–11 7
5.3. Safety
Adverse events with NB32 are consistent with the individ-
ual actions of bupropion and naltrexone. The most common
adverse events are nausea, constipation, headache, and vomiting
[144–147]. Generally, adverse events associated with NB32 are
mild to moderate in severity, occur early in treatment during dose
escalation, and do not result in study discontinuation. The most
common adverse event, nausea, is likely a result of local actions
of naltrexone in the gastrointestinal tract where opioids inﬂuence
gastrointestinal motility [91,159]; however, a low incidence of nau-
sea is also associated with bupropion [121]. Consistent with the
known adverse effects of metformin [160], nausea occurred more
frequently in patients with type 2 diabetes who  were taking met-
formin [147].
Small increases in mean blood pressure and pulse rate have
also been reported with NB32 [144–147]. These effects are con-
sistent with the known hemodynamic effects of bupropion [121]
and may  be attributable to noradrenergic effects. Mean increases
in systolic and diastolic blood pressure of approximately 1 mm Hg
from baseline occurred during the ﬁrst 8 weeks of treatment with
NB32. After 12 weeks, mean blood pressure in NB32-treated sub-
jects returned to baseline. By Week 56, both placebo and NB32
groups exhibited a small decrease from baseline in mean blood
pressure; the reduction was  slightly greater in the placebo group.
Greater weight loss was  associated with greater decreases in mean
blood pressure for both NB32 and placebo, although the reduction
in blood pressure was  less with NB32 than with placebo in subjects
with similar weight loss. A mean increase in pulse rate of 1.5–2.5
beats per minute has also been documented with NB32. The car-
diovascular impact of these sympathomimetic effects of NB32 is
currently being investigated in a trial designed to assess the occur-
rence of major adverse cardiovascular events for NB32 compared to
placebo [161].
Antidepressants are associated with rare occurrences of psychi-
atric symptoms during treatment and after drug cessation [121].
Because NB32 contains an antidepressant, depressive and anxiety
symptoms, as well as serious psychiatric events, were evaluated in
all the COR studies. No differences were observed with NB32 com-
pared to placebo [144–147]. In addition, the COR-I study compared
the effects of sudden vs. tapered cessation of NB32 or placebo and
found no difference in the incidence of adverse events, psychiatric
adverse events, or depressive and anxiety symptoms compared to
placebo (unpublished data on ﬁle at Orexigen Therapeutics, Inc.).
6. Long-term pharmacotherapy for obesity in the United
States
Obesity is a chronic condition that requires long-term treatment
to reduce and maintain a lower body weight [13]. Although lifestyle
intervention is the ideal and safest way to reduce body weight,
most individuals do not achieve clinically meaningful weight loss
with diet and exercise alone [162]. Furthermore, weight regain
after lifestyle intervention or cessation of obesity medications is
common [17,19,163] and patients who  stop taking obesity medi-
cations will likely experience at least some weight regain without
further intervention. Thus, obesity medications facilitate weight
loss and maintenance, which may  yield long-term improvements in
obesity-related comorbidities such as diabetes and cardiovascular
disease.
Weight loss with NB32 in the COR-I and COR-II studies was com-phentermine/topiramate [13,144,146]. All these agents increase
the likelihood that overweight and obese patients will achieve
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linically meaningful weight loss of at least 5% and at least 10%
fter 1 year of treatment.
Similar to NB32, lorcaserin and phentermine/topiramate are
elieved to act primarily in the CNS and each has been reported
o reduce appetite, which may  contribute to weight loss efﬁ-
acy [20,25]. Some of the most common adverse events with
orcaserin (headache, dizziness, fatigue, nausea) [18–20] and phen-
ermine/topiramate (paresthesia, dizziness, dysgeusia, insomnia)
22–24] are consistent with a central mechanism of action. Many
f these adverse events resolve with continued use. In contrast, the
astrointestinal adverse events that occur with orlistat are due to a
eripheral mechanism of action, and usually resolve with reducing
at intake [13–17,164].
Despite the increasing rate of obesity and poor success rate of
ifestyle intervention for weight loss, utilization of obesity pharma-
otherapies is low. Persistence rates for orlistat and sibutramine
withdrawn from the market in 2010 due to increased risk of car-
iovascular events) were less than 10% for 1 year and 2% for 2 years
165]. In 2011, an estimated 2.7 million individuals were taking
besity drugs in the United States [166]. This low utilization of obe-
ity medications, combined with the recent approval of lorcaserin
nd phentermine/topiramate, means that the long-term effects of
urrent obesity medications are largely unknown. Because of the
eterogeneity of obesity, multiple treatment options will enable
are providers and patients to maximize weight loss while min-
mizing safety and tolerability issues. As more obesity therapies
ecome available, obesity medications may  become increasingly
tilized and improve our understanding of the mechanism of action
nd long-term effects of these drugs.
. Summary
The limited success of obesity medications to date can most
ikely be attributed to the complexity of brain pathways that
egulate hunger, food craving and eating behavior. We  are only
eginning to understand the powerful inﬂuence of factors such as
ood and emotion on eating behavior and body weight. In today’s
nvironment where foods that are high in fat and sugar are readily
vailable, neural pathways regulating hedonic drives are sure to
lay a role in weight regain and to limit weight loss attempts.
reclinical studies show that the naltrexone/bupropion combi-
ation acts in hypothalamic brain regions that regulate appetite
nd energy expenditure, while also inﬂuencing eating behavior
hat is mediated by the reward system. The weight loss pro-
uced by NB in humans is likely attributed to these dual actions.
n clinical studies, a consistently substantial proportion of over-
eight and obese subjects responded to NB32 treatment with
t least 5% or 10% weight loss. These treatment responders are
ikely those who would beneﬁt most from NB treatment in clinical
ractice.
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